Abstract
AbstractTremendous progress has been made in the management of chronic lymphocytic leukemia (CLL) in recent years. Anti-CD20 antibodies, inhibitors of Bruton tyrosine kinase (BTK), an inhibitor of B-cell lymphoma 2 (BCL2), and inhibitors of phosphoinositide 3-kinase (PI3K) have all translated into improved outcomes for patients with CLL. Patients are living longer, in remission longer, and experiencing fewer toxicities than in the era of chemoimmunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
